Novel ibuprofen prodrug: A possible promising agent for the management of complications of Alzheimer’s disease

• Published in: Saudi pharmaceutical journal 2024-01, Vol.32 (1), p.101888-101888, Article 101888
• Main Authors: Nayak, Anjali, Raju, Rashu, Das, Paramita, Das, Kuntal, Suvitha, A., Ranjan Meher, Biswa, Alobid, Saad, Almoteer, Ali Ibrahim, Almadani, Moneer E., Alshehri, Ahmed, Alghamdi, Adel, Ahmad, Fuzail, Rabbani, Syed Imam, Asdaq, Syed Mohammed Basheeruddin, Nayeem, Naira
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Animals; Drug effect; Ibuprofen; Novel conjugate; Prodrug
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2023.101888

Alzheimer’s disease (AD) is a severe, varied, and complex brain condition that gradually impairs memory and cognitive function. Epidemiological studies have shown that patients who have a history of long-term NSAID use have a decreased risk of developing AD. The objective of this study is to conduct the structural analysis of a novel ibuprofen prodrug and test its anti-Alzheimer’s properties. Computational and docking studies were conducted using AMBER 18 package. The in-vivo studies were performed using aluminum chloride-induced experimental AD in rats. Adult Wistar rats of either sex were used and treated with aluminum chloride (32.5 mg/kg, p.o) and ibuprofen prodrug (50 mg/kg, p.o) daily for 30 days. The hole-board test and elevated plus maze were conducted on 10th, 20th and 30th day. Further, on 31st day, animals were euthanized and the brain tissue was used for histopathology. The results obtained were subjected to statistical analysis by one-way ANOVA and Dunnet’s test, p